Medical Policy
Ultrasonographic Evaluation of Skin Lesions

Table of Contents
- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References

Policy Number: 303
BCBSA Reference Number: 2.01.59

Related Policies
- Dermatoscopy #519

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members
Ultrasonographic evaluation of skin lesions is INVESTIGATIONAL.
Ultrasonographic evaluation as a technique to assess photo-aging or skin rejuvenation techniques is considered cosmetic in nature, and therefore is NOT MEDICALLY NECESSARY.

Prior Authorization Information
Commercial Members: Managed Care (HMO and POS)
This is NOT a covered service.

Commercial Members: PPO, and Indemnity
This is NOT a covered service.

Medicare Members: HMO BlueSM
This is NOT a covered service.

Medicare Members: PPO BlueSM
This is NOT a covered service.

CPT Codes / HCPCS Codes / ICD-9 Codes
The following codes are included below for informational purposes. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.
Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

**CPT Codes**
There is no specific CPT code for this service.

**ICD-9 Diagnosis Codes**
Investigational for all diagnoses.

**Description**
Ultrasonographic evaluation of skin lesions refers to the use of ultrasound to determine the margins and depth of surface tumors or inflammatory skin conditions. Ultrasound transducers of at least 20 MHz are used.

The following applications of ultrasonographic evaluation have been proposed:
- To assess the margins and depth of melanoma and non-melanoma skin cancers to aid in surgical planning,
- To assess actinic keratoses to determine if cryosurgery is an appropriate therapeutic option,
- To follow the course of connective diseases of the skin (i.e., scleroderma) by evaluating the amount and location of collagen in the dermis, and
- To assess inflammatory skin diseases, such as allergic reactions or psoriasis.

Examples of ultrasonographic evaluations of skin lesions include the Episcan® I-200 Ultrasound System from Longport, Inc. and the DermaScan™ C Ultrasonic System from Cortex Technology. All ultrasonographic evaluations of skin lesions are considered investigational or not medically necessary regardless of the commercial name, the manufacturer or FDA approval status.

**Summary**
The evidence is insufficient for determining whether the use of ultrasound leads to improved health outcomes in patients with skin lesions. No identified study examined whether the use of ultrasonography preoperatively resulted in improved health outcomes, such as lower rates of disease recurrence or increased survival. Given the lack of sufficient high-quality evidence on the impact of ultrasound skin imaging on patient management, this technology is considered investigational.

In addition, due to the cosmetic nature of the application, ultrasound skin imaging is considered not medically necessary to assess photoaging or skin rejuvenation techniques.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No changes to policy statements.</td>
</tr>
<tr>
<td>1/12/2011</td>
<td>New policy, effective 1/12/2011 describing ongoing non-coverage.</td>
</tr>
</tbody>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**
Click on any of the following terms to access the relevant information:
- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

**References**